Press Releases - Renalytix

RenalytixAI and AKESOgen In Joint Venture Partnership for Expanded Testing Capacity and Pharma Services

02.13.19

NEW YORK, Feb. 13, 2019 /PRNewswire/ -- RenalytixAI (AIM: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the completion of a joint venture partnership agreement with AKESOgen, an industry-leading commercial laboratory facility and provider of

RenalytixAI Expands Leadership Team to Support Launch of AI-Enabled Diagnostics for Kidney Disease

02.06.19

Company Adds Clinical and Data Security Expertise to Support KidneyIntelX Clinical Validation, Software and Regulatory Programs NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced the

RenalytixAI Initiates Clinical Validation Study of AI-Enabled KidneyIntelX™ for Diagnosing Fast-Progressing Kidney Disease

01.23.19

Validation study to assess approximately 5,000 patients with participation from a multi-center group of leading U.S. investigators NEW YORK, Jan. 23, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled diagnostics for kidney disease, today announced

RenalytixAI Raises $29 Million to Commercialize AI-Enabled Clinical Diagnostic Solutions for Kidney Disease

11.15.18

Solutions to Improve Detection, Management and Treatment of Kidney Disease, Which Impacts More Than 850 Million Globally Mount Sinai to Collaborate for Launch of Initial Product, KidneyIntelX™, in 2019 NEW YORK, Nov. 15, 2018 /PRNewswire/ -- Renalytix AI plc (LSE AIM: RENX), a developer of